The Contrast Media Wars Get Hot
AmeriNet officials were upset that Mallinckrodt was unwilling to offer AmeriNet the same terms it had Premier. When Mallinckrodt said "no", AmeriNet turned to Bracco.
You may also be interested in...
Amersham Health is applying Big Pharma marketing and R&D strategies to the traditionally stodgy, highly price-sensitive field of diagnostic imaging contrast agents. It has been far more aggressive than competitors in working to make innovation the basis of competition. But some analysts question whether the company can maintain near-to-mid-term growth as it awaits results of its risky, long-term effort in molecular imaging.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.